Divya Koura

1.3k total citations
18 papers, 105 citations indexed

About

Divya Koura is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Divya Koura has authored 18 papers receiving a total of 105 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Oncology and 5 papers in Immunology. Recurrent topics in Divya Koura's work include Acute Myeloid Leukemia Research (6 papers), CAR-T cell therapy research (6 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Divya Koura is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), CAR-T cell therapy research (6 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Divya Koura collaborates with scholars based in United States, Canada and Malaysia. Divya Koura's co-authors include Randy Taplitz, Clare Logan, Amelia Langston, Ila M. Saunders, Marisela Tan, Rebecca Young, Dimitrios Tzachanis, John F. DiPersio, Markus Y. Mapara and Michael R. Loken and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy.

In The Last Decade

Divya Koura

15 papers receiving 104 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Divya Koura United States	6	49	46	26	18	15	18	105
Dai Keino Japan	7	30 0.6×	30 0.7×	38 1.5×	27 1.5×	13 0.9×	35	117
Tomáš Szotkowski Czechia	7	28 0.6×	94 2.0×	42 1.6×	27 1.5×	16 1.1×	36	137
Kannadit Prayongratana Thailand	5	32 0.7×	42 0.9×	13 0.5×	9 0.5×	8 0.5×	20	75
Giovanna Leone Italy	6	25 0.5×	43 0.9×	8 0.3×	17 0.9×	41 2.7×	14	106
Anne C. Wilke Germany	6	69 1.4×	44 1.0×	15 0.6×	41 2.3×	11 0.7×	7	119
Isabel Cano Spain	8	45 0.9×	80 1.7×	43 1.7×	15 0.8×	17 1.1×	21	154
Audrey M. Sigmund United States	6	45 0.9×	46 1.0×	25 1.0×	16 0.9×	21 1.4×	22	116
Satoshi Kaito Japan	7	46 0.9×	61 1.3×	69 2.7×	10 0.6×	14 0.9×	22	156
Eva Bubanská Slovakia	7	30 0.6×	34 0.7×	22 0.8×	24 1.3×	28 1.9×	13	110
Marie‐Pierre Pagès France	6	34 0.7×	61 1.3×	20 0.8×	28 1.6×	17 1.1×	8	140

Countries citing papers authored by Divya Koura

Since Specialization

Citations

This map shows the geographic impact of Divya Koura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Divya Koura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Divya Koura more than expected).

Fields of papers citing papers by Divya Koura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Divya Koura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Divya Koura. The network helps show where Divya Koura may publish in the future.

Co-authorship network of co-authors of Divya Koura

This figure shows the co-authorship network connecting the top 25 collaborators of Divya Koura. A scholar is included among the top collaborators of Divya Koura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Divya Koura. Divya Koura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Koura, Divya, Aaron M. Goodman, Caitlin Costello, et al.. (2025). A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept. Blood Advances. 9(16). 4336–4344.

DiPersio, John F., Guenther Koehne, Nirali N. Shah, et al.. (2024). A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 2873–2873.

DiPersio, John F., Brenda Cooper, Hyung C. Suh, et al.. (2024). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).. Transplantation and Cellular Therapy. 30(2). S237–S238. 4 indexed citations

Shah, Nirali N., Jacques Azzi, Matthew Cooper, et al.. (2024). Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 30(2). S225–S226. 1 indexed citations

Tzachanis, Dimitrios, et al.. (2024). A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis. Cell Transplantation. 33. 4241323105–4241323105. 1 indexed citations

Koehne, Guenther, Benjamin Tomlinson, Hyung C. Suh, et al.. (2023). P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. HemaSphere. 7(S3). e24418bc–e24418bc. 3 indexed citations

Koura, Divya, James Mirocha, Ayad Hamdan, et al.. (2023). A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus. Blood. 142(Supplement 1). 3551–3551. 1 indexed citations

DiPersio, John F., Matthew Cooper, Hyung C. Suh, et al.. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood. 142(Supplement 1). 483–483. 7 indexed citations

Shah, Nirali N., Jacques Azzi, Matthew Cooper, et al.. (2023). Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood. 142(Supplement 1). 4862–4862. 6 indexed citations

10.

Lipinski, Jerry, et al.. (2023). MYOCARDIAL INFARCTION FROM CORONARY THROMBOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA. Journal of the American College of Cardiology. 81(8). 2691–2691.

11.

Cooper, Brenda, Hyung C. Suh, Divya Koura, et al.. (2022). Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse. Blood. 140(Supplement 1). 12973–12975. 1 indexed citations

12.

Koura, Divya, Dimitrios Tzachanis, Edward D. Ball, et al.. (2021). A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care. Blood. 138(Supplement 1). 1816–1816. 2 indexed citations

13.

Saunders, Ila M., Marisela Tan, Divya Koura, & Rebecca Young. (2020). Long‐term Follow‐up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 40(8). 808–841. 12 indexed citations

14.

Logan, Clare, Divya Koura, & Randy Taplitz. (2020). Updates in infection risk and management in acute leukemia. Hematology. 2020(1). 135–139. 44 indexed citations

15.

Koura, Divya, et al.. (2019). Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 20(7). 431–437.e2. 7 indexed citations

16.

Saunders, Ila M., et al.. (2019). A Case of Aplastic Anemia Associated With Long-Term Metronidazole Use. Journal of Pharmacy Practice. 33(4). 540–542. 1 indexed citations

17.

Suessmuth, Yvonne, Divya Koura, Knut Finstermeier, et al.. (2015). Exhaustive TCR Deep Sequencing Reveals That CMV Reactivation Fundamentally Resets Immune Reconstitution after Transplant and Results in Significant Deficits in the Effector Memory TCR Repertoire. Biology of Blood and Marrow Transplantation. 21(2). S69–S70. 1 indexed citations

18.

Koura, Divya & Amelia Langston. (2013). Inherited predisposition to multiple myeloma. Therapeutic Advances in Hematology. 4(4). 291–297. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact